>Mercado de medicamentos injetáveis liofilizados no Médio Oriente e África, por embalagem (frascos, seringas de câmara dupla, cartuchos de câmara dupla e outros), classe de medicamentos (antiinfecciosos, antineoplásicos, diuréticos, inibidores da bomba de protões, anestésicos, anticoagulantes , AINEs, corticosteróides e Outros), Forma (Pó e Líquido), Indicação (Oncologia, Doenças Autoimunes, Distúrbios Hormonais, Doenças Respiratórias, Distúrbios Gastrointestinais, Distúrbios Dermatológicos, Doenças Oftalmológicas e Outras), Via de Administração (Intravenosa/Infusão, Intramuscular e Outros), Utilizador Final (Hospital, Clínicas, Assistência Médica Domiciliária e Outros), Canal de Distribuição (Concurso Direto, Vendas a Retalho e Outros), País (Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Kuwait, Egito e Resto do Médio Oriente e África) Tendências e Previsões do Sector para 2028.
Análise de mercado e insights: Mercado de drogas injetáveis liofilizadas no Médio Oriente e em África
Espera-se que o mercado de drogas injetáveis liofilizadas ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 4,2% no período de previsão de 2021 a 2028 e deverá atingir os 208,14 milhões de USD até 2028. Espera-se que o aumento das condições crónicas de saúde em todo o mundo funcione como um motor para aumentar a procura do mercado de medicamentos injectáveis liofilizados.
A liofilização é outro termo para liofilização. É uma técnica de isolar um material sólido de um solvente por congelação e evaporação da solução sob vácuo. Considera-se que os produtos liofilizados têm uma vida útil mais longa do que os medicamentos convencionais e, por isso, são favorecidos. A proteção de produtos biológicos, proteínas, microrganismos anticorpos, parenterais, plasma sanguíneo, enzimas, reagentes de diagnóstico, vacinas e nutracêuticos é geralmente feita através de liofilização. Para manter estáveis alguns ingredientes a granel instáveis, é necessária a liofilização do injetável estéril.
Espera-se que o crescente avanço tecnológico dos medicamentos injetáveis liofilizados atue como um impulsionador para aumentar a procura do mercado de medicamentos injetáveis liofilizados. Espera-se que o aumento do número de recolhas de produtos para medicamentos liofilizados e tipos de embalagens atue como uma restrição do mercado de medicamentos injetáveis liofilizados. Espera-se que o aumento das aprovações regulamentares para medicamentos liofilizados atue como uma oportunidade para aumentar a procura do mercado de medicamentos injetáveis liofilizados. Espera-se que os fatores associados ao fabrico de frascos liofilizados para produtos parenterais desafiem a procura do mercado de medicamentos injetáveis liofilizados.
O relatório de mercado de medicamentos injetáveis liofilizados fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos. Para compreender a análise e o cenário do mercado de medicamentos injetáveis liofilizados, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado Drogas injetáveis liofilizadas
O mercado dos medicamentos injetáveis liofilizados está categorizado em sete segmentos notáveis que se baseiam na embalagem, classe do medicamento, forma, indicação, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base nas embalagens, o mercado dos medicamentos injetáveis liofilizados está segmentado em frascos, seringas de dupla câmara, cartuchos de dupla câmara e outros. Em 2021, espera-se que o segmento dos frascos domine o mercado dos medicamentos injetáveis liofilizados porque a maioria dos medicamentos injetáveis liofilizados são embalados em frascos, pelo que é influente e também está a crescer no mercado.
- Com base na classe de medicamentos, o mercado dos medicamentos injetáveis liofilizados está segmentado em anti-infecciosos, antineoplásicos, diuréticos, inibidores da bomba de protões, anestésicos, anticoagulantes, AINEs, corticosteróides e outros. Em 2021, prevê-se que o segmento anti-infeccioso domine o mercado dos medicamentos injetáveis liofilizados devido ao aumento da procura de antibióticos e medicamentos antivirais em todo o mundo.
- Com base na forma, o mercado dos medicamentos injetáveis liofilizados está segmentado em pó e líquido. Em 2021, prevê-se que o segmento do pó domine o mercado dos medicamentos injetáveis liofilizados devido ao seu armazenamento fácil e seguro, para além do transporte para todo o mundo.
- Com base na indicação, o mercado dos medicamentos injetáveis liofilizados está segmentado em oncologia, doenças autoimunes, distúrbios hormonais, doenças respiratórias, distúrbios gastrointestinais, distúrbios dermatológicos, doenças oftalmológicas e outros. Em 2021, prevê-se que o segmento da oncologia domine o mercado dos medicamentos injetáveis liofilizados devido à disponibilidade de um maior número de medicamentos injetáveis liofilizados para oncologia.
- Com base na via de administração, o mercado dos medicamentos injetáveis liofilizados está segmentado em intravenoso/infusão, intramuscular e outros. Em 2021, prevê-se que o segmento intravenoso/infusão domine o mercado dos medicamentos injetáveis liofilizados devido à biodisponibilidade de 100% do medicamento por esta via de administração.
- On the basis of end user, the lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market due to the financial capabilities of hospitals to purchase luxurious equipment along with the presence of trained professionals to administer them.
- On the basis of distribution channel, the lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market because most of the service providers buy the lyophilized injectable drugs from manufacturers and it is noticed that revenue from direct sales is higher, so it is influential as well as growing in the market.
Middle East and Africa Lyophilized Injectable Drugs Market Country Level Analysis
Middle East and Africa lyophilized injectable drugs market is analysed and market size information is provided by the country, packaging, drug class, form, indication, route of administration, end user and distribution channel as referenced above.
The countries covered in the Middle East and Africa lyophilized injectable drugs market are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa.
Saudi Arabia is expected to dominate in the Middle East and Africa lyophilized injectable drugs market due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
New Product Launches by Manufacturers is creating new opportunities for Players in the Lyophilized Injectable Drugs Market
The lyophilized injectable drugs market also provides you with detailed market analysis for every country growth in lyophilized injectable drugs industry with lyophilized injectable drugs market sales, impact of advancement in the lyophilized injectable drugs market and changes in regulatory scenarios with their support for the lyophilized injectable drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lyophilized Injectable Drugs Market Share Analysis
O panorama competitivo do mercado de medicamentos injetáveis liofilizados fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado de medicamentos injetáveis liofilizados no Médio Oriente e em África.
As principais empresas abrangidas no relatório de mercado de medicamentos injetáveis liofilizados do Médio Oriente e África são a Genex Pharma, a Aristopharma Ltd., a Pfizer Inc., a Viatris Inc., a Gilead Sciences, Inc., a Jubilant Generics Limited – A Jubilant Pharma Company , Novartis AG, Otsuka America Pharmaceutical, Inc., Zydus Cadila, Cipla Inc., Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., Sanofi, Celon Laboratories Pvt. Ltd. e Baxter, entre outros players nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos contratos e acordos são também iniciados por empresas em todo o mundo que também estão a acelerar o mercado dos medicamentos injetáveis liofilizados.
- Em novembro de 2019, a Pfizer, Inc. anunciou que a sua divisão, denominada Upjohn, foi combinada com a Mylan NV e formou uma nova empresa chamada Viatris Inc. o seu produto no mercado.
A colaboração, as joint ventures e outras estratégias dos players do mercado estão a potenciar o mercado da empresa no mercado das drogas injetáveis liofilizadas, o que também oferece o benefício para a organização melhorar a sua oferta para o mercado das drogas injetáveis liofilizadas.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGING LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN CHRONIC HEALTH CONDITIONS
6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE
6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES
6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS
6.1.5 TECHNOLOGICAL ADVANCEMENTS
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLESTICK INJURIES
6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE
6.3 OPPORTUNITIES
6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS
6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS
6.3.3 QUALITY CONCERNS
6.4 CHALLENGES
6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS
6.4.2 TIME-CONSUMING PROCESS AND HIGH COST
7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT IN DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVE
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING
8.1 OVERVIEW
8.2 VIALS
8.3 DUAL-CHAMBER SYRINGES
8.4 DUAL-CHAMBER CARTRIDGES
8.5 OTHERS
9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFECTIVE’S
9.2.1 ANTIBIOTICS
9.2.1.1 Azithromycin
9.2.1.2 Doxycycline
9.2.1.3 Vancomycin
9.2.1.4 Polymyxin B
9.2.1.5 Piperacillin
9.2.1.6 Tazobactam
9.2.1.7 Others
9.2.2 ANTIFUNGAL
9.2.2.1 Mycamine
9.2.2.2 Caspofungin Acetate
9.2.2.3 Isavuconazonium Sulfate
9.2.2.4 Amphotericin
9.2.2.5 Others
9.2.3 ANTIVIRAL
9.2.3.1 Acyclovir
9.2.3.2 Ganciclovir
9.2.3.3 Remdesivir
9.2.3.4 Others
9.2.4 OTHERS
9.3 ANTINEOPLASTIC
9.3.1 METHOTREXATE
9.3.2 GEMCITABINE
9.3.3 CYTARABINE
9.3.4 FLUDARABINE
9.3.5 DOXORUBICIN
9.3.6 OXALIPLATIN
9.3.7 ZOLEDRONIC ACID
9.3.8 OTHERS
9.4 DIURETICS
9.4.1 CHLOROTHIAZIDE
9.4.2 ETHACRYNIC ACID
9.4.3 ACETAZOLAMIDE
9.4.4 OTHERS
9.5 PROTON PUMP INHIBITOR
9.5.1 ESOMEPRAZOLE SODIUM
9.5.2 PANTOPRAZOLE SODIUM
9.5.3 OMEPRAZOLE
9.5.4 OTHERS
9.6 ANESTHETIC
9.6.1 VECURONIUM BROMIDE
9.6.2 SODIUM THIOPENTAL
9.6.3 LIDOCAINE
9.6.4 OTHERS
9.7 ANTICOAGULANT
9.7.1 COUMADIN
9.7.2 UROKINASE
9.7.3 ANTITHROMBIN (RECOMBINANT)
9.7.4 APIXABAN
9.7.5 RIVAROXABAN
9.7.6 OTHERS
9.8 NSAID’S
9.8.1 INDOMETHACIN
9.8.2 IBUPROFEN
9.8.3 DICLOFENAC
9.8.4 KETOROLAC
9.8.5 OTHERS
9.9 CORTICOSTEROIDS
9.9.1 HYDROCORTISONE
9.9.2 METHYLPREDNISOLONE
9.9.3 OTHERS
9.1 OTHERS
10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 AUTOIMMUNE DISEASES
11.4 HORMONAL DISORDERS
11.5 RESPIRATORY DISEASES
11.6 GASTROINTESTINAL DISORDERS
11.7 DERMATOLOGICAL DISORDERS
11.8 OPHTHALMIC DISEASES
11.9 OTHERS
12 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS/INFUSION
12.3 INTRAMUSCULAR
12.4 OTHERS
13 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 KUWAIT
15.1.6 ISRAEL
15.1.7 REST OF MIDDLE EAST & AFRICA
16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 CIPLA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 NOVARTIS AG
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 BAXTER
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ZYDUS CADILA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AFFY PHARMA PVT LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AMNEAL PHARMACEUTICALS LLC
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARISTOPHARMA LTD.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 CELON LABORATORIES PVT.LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 CIRONDRUGS
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 GENEX PHARMA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GILEAD SCIENCES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 OTSUKA AMERICA PHARMACEUTICAL, INC
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SANOFI
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS
TABLE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 9 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 58 MIDDLE EAST & AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 77 SOUTH AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 79 SOUTH AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 80 SOUTH AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 81 SOUTH AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 82 SOUTH AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 96 SAUDI ARABIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 99 SAUDI ARABIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 100 SAUDI ARABIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 101 SAUDI ARABIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 102 SAUDI ARABIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 103 SAUDI ARABIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 104 SAUDI ARABIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 105 SAUDI ARABIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 106 SAUDI ARABIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 107 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 108 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 109 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 111 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 112 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 113 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 114 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 115 U.A.E. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 116 U.A.E. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 117 U.A.E. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 118 U.A.E. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 119 U.A.E. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 120 U.A.E. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 121 U.A.E. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 122 U.A.E. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 123 U.A.E. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 124 U.A.E. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 125 U.A.E. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 126 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 127 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 130 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 131 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 132 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 134 EGYPT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 138 EGYPT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 139 EGYPT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 140 EGYPT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 141 EGYPT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 142 EGYPT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 143 EGYPT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 144 EGYPT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 145 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 146 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 147 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 149 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 153 KUWAIT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 164 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 165 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 166 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 170 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 171 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 172 ISRAEL ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 173 ISRAEL ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 174 ISRAEL ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 175 ISRAEL ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 176 ISRAEL ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 177 ISRAEL DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 178 ISRAEL PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 179 ISRAEL ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 180 ISRAEL ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 181 ISRAEL NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 182 ISRAEL CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 183 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 184 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 185 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 187 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 188 REST OF MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
FIGURE 15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020
FIGURE 16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020
FIGURE 20 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020
FIGURE 24 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020
FIGURE 28 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)
FIGURE 48 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
